OPIANT PHARMACEUTICALS, INC. Uncategorized Contracts & Agreements
45 Contracts & Agreements
- Description of the Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 15, 2022)
- Director Agreement, effective March 18, 2021, by and between Opiant Pharmaceuticals, Inc. and Dr. Lorianne Masuoka (Filed With SEC on March 22, 2021)
- Description of the Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 4, 2021)
- Amendment of Solicitation/Modification of Contract (Filed With SEC on December 14, 2020)
- Description of the Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 4, 2020)
- Open Market Sale AgreementSM, dated November 14, 2019, by and between Opiant Pharmaceuticals, Inc. and Jefferies LLC (Filed With SEC on November 14, 2019)
- Director Agreement, effective October 29, 2018, by and between Opiant Pharmaceuticals, Inc. and Craig A. Collard (Filed With SEC on October 30, 2018)
- Director Agreement, effective June 12, 2018, by and between Opiant Pharmaceuticals, Inc. and Richard Daly (Filed With SEC on June 12, 2018)
- Supplemental Engagement Letter, dated September 8, 2017, by and between the Company and Torreya Partners (Europe) LLP (Filed With SEC on September 14, 2017)
- Offer Letter, dated August 29, 2017, by and between the Company and David OToole (Filed With SEC on September 5, 2017)
- THIRD AMENDMENT TO SENIOR ADVISOR AGREEMENT (Filed With SEC on June 14, 2017)
- AMENDMENT TO AMENDED AND RESTATED CONSULTINGAGREEMENT (Filed With SEC on June 2, 2017)
- THIRD AMENDMENT TO SENIOR ADVISOR AGREEMENT (Filed With SEC on March 15, 2017)
- Senior Advisor Agreement (Filed With SEC on March 15, 2017)
- First Amendment toSenior Advisor Agreement (Filed With SEC on March 15, 2017)
- SecondAmendment to Senior Advisor Agreement (Filed With SEC on March 15, 2017)
- OPIANT PHARMACEUTICALS, INC. DIRECTOR AGREEMENT (Filed With SEC on November 10, 2016)
- Lightlake Therapeutics Inc. 96-98 Baker Street First Floor London,W1U 6TJ United Kingdom Phone: 44 20 3617 8739 www.lightlaketherapeutics.com (Filed With SEC on October 28, 2016)
- Lightlake Therapeutics Inc. 96-98 Baker Street First Floor London, W1U6TJ United Kingdom Phone: 44 20 3617 8739 www.lightlaketherapeutics.com (Filed With SEC on October 28, 2016)
- AMENDED AND RESTATEDINTEREST AGREEMENT (Filed With SEC on October 28, 2016)
- Lightlake Therapeutics Inc. 96-98 Baker Street First Floor London,W1U 6TJ United Kingdom Phone: 44 20 3617 8739 www.lightlaketherapeutics.com (Filed With SEC on October 28, 2016)
- Lightlake Therapeutics Inc. 96-98 Baker Street First Floor London, W1U6TJ United Kingdom Phone: 44 20 3617 8739 www.lightlaketherapeutics.com (Filed With SEC on October 28, 2016)
- AMENDED AND RESTATED INTEREST AGREEMENT (Filed With SEC on October 28, 2016)
- REGULATORY AND STRATEGIC ADVISOR CONSULTANCYAGREEMENT (Filed With SEC on October 28, 2016)
- Torreya Partners (Europe) LLP isauthorised and regulated by the Financial Conduct Authority. (Filed With SEC on October 28, 2016)
- AMENDED AND RESTATED MATERIAL TRANSFER, OPTION AND RESEARCHLICENSE AGREEMENT between OPIANT PHARMACEUTICALS, INC. and AEGIS THERAPEUTICS, LLC (Filed With SEC on June 8, 2016)
- 11770 Bernardo Plaza Court, Suite 353 San Diego, CA 92128 Phone: 858-618-1400 Facsimile 858-618-1441 Confidential (Filed With SEC on June 8, 2016)
- OPIANTPHARMACEUTICALS, LNC. DIRECTORAGREEMENT (Filed With SEC on May 11, 2016)
- OPIANT PHARMACEUTICALS, INC. DIRECTOR AGREEMENT (Filed With SEC on May 11, 2016)
- Third Amendment to Executive Letter ofReappointment (Filed With SEC on April 15, 2016)
- Third Amendment to Executive Letter ofAppointment (Filed With SEC on April 15, 2016)
- LIGHTLAKETHERAPEUTICS INC. 445Park Avenue, 9th Floor NewYork, NY STOCKOPTION GRANT (Filed With SEC on October 29, 2015)
- LIGHTLAKETHERAPEUTICS INC. 445Park Avenue, 9th Floor NewYork, NY STOCKOPTION GRANT (Filed With SEC on October 29, 2015)
- LIGHTLAKETHERAPEUTICS INC. 445Park Avenue, 9th Floor NewYork, NY STOCKOPTION GRANT (Filed With SEC on October 29, 2015)
- MATERIAL TRANSFER, OPTION AND RESEARCHLICENSE AGREEMENT (Filed With SEC on October 26, 2015)
- ConfidentialTreatment Requested by Lightlake Therapeutics Inc. IRS EmployerIdentification No. 46-4744124 Confidentialtreatment requested with respect to certain portions hereof... (Filed With SEC on June 12, 2015)
- MATERIAL TRANSFER, OPTION AND RESEARCHLICENSE AGREEMENT (Filed With SEC on March 17, 2015)
- Second Amendment to Executive Letterof Reappointment (Filed With SEC on February 25, 2014)
- Second Amendment to Executive Letterof Appointment (Filed With SEC on February 25, 2014)
- Amendment to Executive Letter of Reappointment (Filed With SEC on October 29, 2013)
